Who is at risk for NAFLD?

 

Fatty liver is typically associated with the following:

  • type 2 diabetes
  • obesity
  • high cholesterol
  • high blood pressure
  • insulin resistance

There is a silent epidemic of NAFLD in Ireland which, if left undiagnosed and untreated, may lead to cirrhosis of the Liver. However, awareness among patients and healthcare providers in this country is extremely low, leading to underdiagnoses, under-treatment and increased mortality.

 

What is non-alcoholic fatty liver disease?

 

NAFLD is defined as an excess of fat in the liver in the absence of increased alcohol intake. It may develop as:

Simple steatosis (fat): the accumulation of fat in the liver, which may slowly progress to liver inflammation and scar tissue (fibrosis) over many decades.

Non-alcoholic steatohepatitis (NASH): the more progressive and aggressive subtype of NAFLD, where inflammation results in cellular damage leading to fibrosis/cirrhosis.

It is estimated that 25-30% of the global population have NAFLD, and 5-12% develop NASH. A recent Irish NAFLD screening initiative in 2017 of patients with type 2 diabetes mellitus (T2DM) reported that that one in five had advanced fibrosis/cirrhosis.

 

How is NAFLD diagnosed?

 

Research has proven that up to 80% of T2DM patients with NAFLD have normal liver blood tests. Consequently, the European Association for the Study of the Liver (EASL) Clinical Practice Guidelines (2016), strongly recommend that T2DM patients should be screened for NAFLD irrespective of liver enzyme blood levels, since T2DM patients are at risk of liver fibrosis.

To screen for NAFLD, a unique ultrasound-based technology called Vibration Controlled Transient Elastography or FIBROSCAN® is used to measure liver stiffness, a marker of liver fibrosis. This non-invasive and painless method has the advantage of also tracking changes in liver fibrosis over time including post treatment assessments.  

 

What is the treatment for NAFLD?

 

The main treatment is lifestyle intervention including diet and exercise. Studies have reported that 7–10% weight loss sustained over 48-weeks results in significant improvement in liver steatosis and inflammation. Lifestyle intervention can improve and reverse NAFLD/NASH, provided significant weight loss is achieved.

The 2016 European guidelines recommend also that the aggressive form of NAFLD (NASH) should be identified in patients at risk – such as those with T2DM or metabolic syndrome, and over 50 years of age. Given the potentially life threatening complications of undiagnosed liver disease, awareness of liver health in patients with diabetes is critical and should be incorporated in diabetic care pathways.

 


Source: Professor Suzanne Norris,
Consultant Hepatologist/Gastroenterologist, St James’s Hospital & Liver Wellness
Professor in Hepatology & Gastroenterology, Trinity College Dublin

Further information at: www.liverwellness.ie